Compare Regeneron Pharmaceuticals Inc (REGN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $743.2 (market cap $76.14B), while ABRDN Physical Gold Shares ETF trades at $39.81 (market cap $7.03B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.8× ABRDN Physical Gold Shares ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| REGN | SGOL | |
|---|---|---|
Market Cap | $76.14B | $7.03B |
Volume | 500,239 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $852.03 | $51.41 |
52-Week Low | $557.73 | $37.54 |
Typical Hold Time | 107 Days | 57 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SGOL is trading at $39.02, down 1.66% with bearish technical signals dominating across moving averages and oscillators. The stock faces significant resistance at current levels with all support and resistance clustered around $39. Recent market sentiment reflects pressure from rising Treasury yields and Federal Reserve policy uncertainty, though some technical indicators like the 12-day RSI at 24.81 suggest potential oversold conditions.
The outlook remains challenging with persistent bearish momentum, though the deeply oversold RSI reading indicates potential for near-term stabilization. Investment opportunities exist for contrarian investors seeking gold exposure amid inflation concerns, while risks include continued pressure from rising interest rates and dollar strength that could push prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
